Systemic autoinflammatory diseases are driven by abnormal activation of innate immunity 1 . Herein we describe a new disease caused by high-penetrance heterozygous germline mutations in TNFAIP3, which encodes the NF-kB regulatory protein A20, in six unrelated families with early-onset systemic inflammation. The disorder resembles Behçet's disease, which is typically considered a polygenic disorder with onset in early adulthood 2 . A20 is a potent inhibitor of the NF-kB signaling pathway 3 . Mutant, truncated A20 proteins are likely to act through haploinsufficiency because they do not exert a dominant-negative effect in overexpression experiments. Patient-derived cells show increased degradation of IkBa and nuclear translocation of the NF-kB p65 subunit together with increased expression of NF-kB-mediated proinflammatory cytokines. A20 restricts NF-kB signals via its deubiquitinase activity. In cells expressing mutant A20 protein, there is defective removal of Lys63-linked ubiquitin from TRAF6, NEMO and RIP1 after stimulation with tumor necrosis factor (TNF). NF-kB-dependent proinflammatory cytokines are potential therapeutic targets for the patients with this disease.
l e t t e r s Independently, we performed whole-exome sequencing in a family of Italian ancestry (family 2) with an affected mother (P4) and daughter (P6). The family history was positive for a dominantly inherited inflammatory disease ( Fig. 1a) . Patients P4, P6 and P5, who is the sister of P4 and aunt of P6, had in common oral and genital ulcers and polyarthritis. Patient P6 was initially diagnosed with an earlyonset severe autoimmune condition resembling systemic lupus erythematosus (SLE), with central nervous system (CNS) vasculitis and anterior uveitis ( Fig. 1b and Supplementary Table 1 ). We identified 30 new candidate variants that were shared by patients P4 and P6, including a new variant in TNFAIP3. Sanger sequencing of patient P5 and the three unaffected family members confirmed that the new variant, p.Phe224Serfs*4, segregated with the inflammatory phenotype ( Fig. 1a) . Patient P6 did not have mutations in genes associated with early-onset autoimmune diseases 8, 9 . We noted that family 1 and family 2 shared new variants in a single candidate gene, TNFAIP3 (NM_006290.2; Supplementary Fig. 2a ).
Screening of an additional 150 patients with clinically similar disease identified three new nonsense and frameshift variants in families of Turkish (family 3), European-American (family 4) and Dutch (family 5) ancestry. In total, we identified five heterozygous truncating mutations in TNFAIP3 in five families (Fig. 1a , Table 1 and Supplementary Fig. 2b) . Targeted sequencing in 384 Turkish and 384 Japanese adult-onset Behçet's disease cases from genome-wide association studies identified one patient with a new frameshift mutation in TNFAIP3, encoding p.Pro268Leufs*19 ( Supplementary Fig. 2c) , which was subsequently identified in her two affected daughters. The mutations identified were considered (c) Schematic of the A20 protein domains. The deubiquitinase activity of A20 is mediated by the OTU domain, and the ZnF domains mediate A20 ubiquitin ligase activity and binding to Lys63-linked ubiquitin chains. The locations of the variants are indicated with red arrows. The variants are predicted to affect A20 protein interactions, dimerization and enzymatic activities. (d,e) Reduced A20 expression in patient-derived PBMCs and fibroblasts. (d) Whole-cell lysates were prepared from PBMCs isolated from three patients from family 1 and a healthy donor (C1) as well as from purified control lymphocytes (Lym). Immunoblotting was performed against the N terminus of A20. (e) Whole-cell lysates from cultured fibroblast cells derived from a healthy donor (C2) and patient P6 were either blotted with antibody specific to the N terminus of A20 (lanes 3 and 4) or subjected to immunoprecipitation with one antibody to the N terminus of A20 (IP) and subsequently blotted with a different antibody to the N terminus of A20 (IB; lanes 5 and 6). 293T lysates from transfections to express FLAG-tagged wild-type A20 (lane 1) or the A20 Leu227* mutant (lane 2) served as controls. npg l e t t e r s pathogenic on the basis of proper family segregation with the inflammatory phenotype and their absence from the Exome Aggregation Consortium (ExAC) database, dbSNP and our exome database of more than 500 exomes. Previously, frameshift mutations in TNFAIP3 have been reported only in tumor tissues in the form of biallelic somatic mutations 10 . The pathogenic variants from our study are predicted to result in truncated proteins, suggesting haploinsufficiency or a dominant-negative effect for the mutant A20 proteins. A20 is a 790-residue protein that consists of an N-terminal ovarian tumor (OTU) domain followed by seven zinc-finger (ZnF) domains 11 (Fig. 1c) . Five of the six disease-associated TNFAIP3 mutations map to the OTU domain, which mediates the deubiquitinase activity, and result in mutant, truncated proteins of similar length. The remaining disease-associated variant, p.Thr604Argfs*93, resides in the ZnF4 domain, which recognizes Lys63-linked ubiquitin chains 12, 13 and is also essential for A20 E3 ubiquitin ligase activity 12, 13 and dimerization 14 . The expression of wild-type A20 was reduced in patientderived peripheral blood mononuclear cells (PBMCs) and fibroblasts, whereas mutant proteins were not detectable ( Fig. 1d,e ). We suspect that mutant proteins are not stable and undergo degradation.
We assessed the activity of each mutant A20 protein using a nuclear factor (NF)-κB luciferase assay. Overexpressed mutant proteins failed to suppress TNF-induced NF-κB activity in transfected human embryonic kidney (HEK) 293T cells ( Fig. 2a) and a human T cell leukemia cell line (Jurkat cells) ( Supplementary Fig. 3 ). Wildtype A20 suppresses NF-κB activity, and cotransfection to express mutant, truncated A20 protein with wild-type A20 did not reverse this outcome, suggesting that the mutant protein does not have a dominantnegative effect ( Fig. 2a) . IκBα kinase (IKK)-mediated phosphorylation of IκBα, resulting in IκB degradation and subsequent nuclear translocation of the associated p50-p65 NF-κB heterodimer, is an essential step in activation of the canonical NF-κB pathway. To define the relationship between the A20 mutants and NF-κB induction in vivo, we studied the activity of the canonical NF-κB pathway in response to stimulation with TNF. Stimulated patient-derived cells showed increased phosphorylation of IKKα/IKKβ, increased phosphorylation of the mitogen-activated protein (MAP) kinases p38 and JNK, and increased degradation of IκBα in comparison to the controls (Fig. 2b,c and Supplementary Fig. 4a,b ). Consistent with these findings, we observed increased nuclear translocation of p65 in patient-derived Enhanced NF-κB signaling in transiently transfected 293T cells and patient-derived cells. (a) A20 mutants do not antagonize the inhibitory effects of wild-type A20 on TNF-induced NF-κB activation. 293T cells were transiently transfected with an NF-κB reporter plasmid, a Renilla luciferase control vector, and expression plasmids for GFP-tagged wild-type or mutant A20. Plasmid expressing IκBα served as a positive control. Results are plotted as firefly luciferase activity normalized to Renilla luciferase activity to compensate for differences in transfection efficiency. npg l e t t e r s PBMCs ( Fig. 2d and Supplementary Fig. 5a ) and fibroblasts, both at rest and after stimulation with TNF ( Fig. 2e and Supplementary  Fig. 5b,c) . These data are strong evidence for enhanced signaling in the NF-κB pathway in A20-deficient cells. The NF-κB signaling cascade is under tight regulation by a number of post-translational modifications, including ubiquitination 15 . A20 restricts cellular activation by cleaving Lys63-linked ubiquitin chains from target substrates such as IKKγ (also known as NEMO), RIP1 and TRAF6 (ref. 12) . Through its E3 ubiquitin ligase activity, A20 adds Lys48linked ubiquitin chains, targeting proteins for proteasome-mediated degradation 11, 16 . Upon activation with TNF, TNFR forms a primary NF-κB-activating signaling complex with TRADD, TRAF2 and RIP1. Consistent with reduced cellular levels of A20 in the cells of patients harboring TNFAIP3 truncation-causing mutations, patient-derived PBMCs displayed reduced recruitment of A20 to the TNFR complex in comparison to cells from healthy donors (Fig. 3a) . To investigate whether the A20 mutants still retained their deubiquitinase function, wild-type and mutant A20 constructs were cotransfected into 293T cells with plasmids encoding Lys63-linked ubiquitin and the A20 ubiquitination targets RIP1, NEMO and TRAF6 (Fig. 3b-d) . (a) Reduced recruitment of mutant A20 to the TNFR signaling complex. PBMCs from patient P4 and a healthy control were stimulated with TNF for the indicated times. Whole-cell lysates were subjected to immunoprecipitation with antibody against TNFR1, TRAF2 or RIP1, and the precipitates were blotted with antibody against the N terminus of A20 and reblotted with antibodies against TNFR1, TRAF2, RIP1 and Ubc13. (b-d) A20 mutants lose their ability to deubiquitinate Lys63-linked ubiquitin chains but do not antagonize the deubiquitinase function of wild-type A20. 293T cells were transiently transfected with expression plasmids for the A20 target proteins RIP1 with a Myc tag (b), NEMO (c) and TRAF6 (d), together with plasmids for HA-Lys63-uboquitin (Ub) and GFP-tagged wild-type or mutant A20. Cells were collected 48 h later, and equal amounts of the whole-cell lysates were subjected to immunoprecipitation with antibodies against the respective target proteins. High-molecular-weight (HMW) ubiquitin aggregates (top) were detected by immunoblotting the precipitates with an HA-specific antibody.
As controls for transfection efficiency, cell lysates were also blotted with antibody against each target protein (middle) or antibody against the N terminus of A20 or the GFP tag (bottom). (e,f) TNF-stimulated patient-derived PBMCs (e) or fibroblasts (f) showed increased abundance and increased molecular weight of Lys63-ubiquitinated NEMO as a result of insufficient A20 deubiquitinase activity. Primary cells from a patient and a healthy control were stimulated with TNF for the indicated times. Whole-cell lysates were subjected to immunoprecipitation with antibody against Lys63-linked ubiquitin, and the precipitates were blotted with antibodies against NEMO and ubiquitin. Cell lysates were also blotted with antibodies against the target protein and β-actin as internal controls. Red arrows point to the differences in lines used for comparison.
npg l e t t e r s Cells transfected to express various diseaseassociated A20 mutants showed a marked defect in the deubiquitination of each of these target molecules, and cells cotransfected to express wild-type and mutant A20 molecules, mimicking the situation in patients, had intermediate levels of deubiquitination. Consistent with the transfection data, TNFR1 signaling complexes from patients with TNFAIP3 mutations accumulated sustained levels of Lys63-ubiquitinated NEMO and RIP1 and accumulated high-molecular-weight ubiquitin aggregates ( Fig. 3e,f, top, lanes 5-8 and Supplementary Fig. 6a,b, lanes 5-8) . In comparison, in PBMCs and fibroblasts from healthy controls, the abundance of high-molecular-weight ubiquitin aggregates gradually decreased over time after stimulation with TNF ( Fig. 3e,f, top, lanes  1-4 and Supplementary Fig. 6a,b, lanes 1-4) . Taken together, these results indicate that inefficient deubiquitination of A20 target proteins might explain higher NF-κB signaling activity in A20-mutant cells.
Active NF-κB subunits promote the transcription of genes encoding proinflammatory cytokines, such as IL-1β, IL-6 and TNF, and facilitate the differentiation and activation of a variety of lymphocyte lineages. Multiple experiments showed evidence of increased expression of NF-κB target genes in patient-derived immune cells (Supplementary Figs. 7 and 8) . Levels of several proinflammatory cytokines were substantially higher in serum from patients and in the supernatants of stimulated patient-derived PBMCs relative to cells from healthy controls (Fig. 4a,b) . Intracellular cytokine staining also showed increased polarization toward T helper type 9 (T H 9) and type 17 (T H 17) CD4 + effector cell lineages, a finding that is consistent with the participation of IL-1β signaling in the differentiation of these npg l e t t e r s lineages, and these lineages may further contribute to tissue inflammation in A20-deficient patients (Fig. 4c) . Finally, the frequency of CD14 + inflammatory monocytes was significantly higher in patients than in healthy controls (Fig. 4d) .
Recent studies in mouse macrophages lacking A20 suggest that A20 functions as a negative regulator of the Nlrp3 inflammasome independently of its role in NF-κB regulation 17, 18 . Consistent with these data, patient-derived cells showed constitutive activation of the NLRP3 inflammasome ( Fig. 5a) , which resulted in activation of caspase-1 and increased secretion of active IL-1β and IL-18 (Fig. 4b) .
Patient-derived PBMCs exhibited enhanced NLRP3 inflammasome-mediated caspase-1 activation and secreted IL-1β in response to lipopolysaccharide (LPS) priming alone, and this effect was attenuated by use of a phospholipase C (PLC) inhibitor, an adenylate cyclase activator or MCC950, all of which are known NLRP3 inflammasome inhibitors 19, 20 (Fig. 5b) . Furthermore, initial experience in a patient with an agent targeting IL-1β has been positive ( Fig. 5c) .
In summary, this is the first report, to our knowledge, of a human disease that we are calling haploinsufficiency of A20 (HA20), caused by high-penetrance loss-of-function germline mutations in TNFAIP3. The findings of multiple nonsense and frameshift variants associated with impaired regulatory function of A20 provide strong evidence that these mutations are pathogenic. Although patients with HA20 and Behçet's disease have similar symptoms, the underlying genetics are distinct. Most sporadic late-onset Behçet's disease cases are not caused by highly penetrant germline mutations in TNFAIP3. A20-deficient mice (Tnfaip3 −/− ) display persistent NF-κB activation, spontaneous multiorgan inflammation and early lethality 21 . Aging heterozygous mice (Tnfaip3 +/− ) develop autoantibodies resembling those in human autoimmune conditions 15 . Targeted ablation of A20 in specific hematopoietic cells in murine models leads to phenotypes reminiscent of autoimmunity [22] [23] [24] . Although five patients in our study developed autoantibodies, an overt autoimmune disease was only diagnosed in patient P6. Notably, none of our patients have developed lymphomas or other malignancies.
TNFAIP3 variants have been linked to many human diseases 15 . Somatic inactivating mutations in TNFAIP3 have been described in B cell lymphomas, suggesting that A20 acts as a tumor suppressor 25 . Common low-penetrance coding and noncoding variants in TNFAIP3 have been associated with multiple autoimmune diseases [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] and susceptibility to allergy and asthma 37 . The current study, however, is the first, to our knowledge, to delineate the consequences of germline inactivating TNFAIP3 mutations in human biology.
Next-generation sequencing will likely identify other rare monogenic inflammatory diseases, possibly involving genes in the same pathway, which might further inform genetic studies of common polygenic immune diseases [38] [39] [40] . There are also potential therapeutic implications from studying patients with monogenic diseases such as HA20 that may apply to more common inflammatory conditions such as Behçet's disease. 
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